Mark Velleca, M.D., Ph.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mark Velleca, M.D., Ph.D.
Mark Velleca, M.D., Ph.D. is recorded as CEO and Board Member at Black Diamond Therapeutics, Inc. (BDTX). Black Diamond Therapeutics, Inc. reported in an 8-K filed September 18, 2023 that Mark Velleca, M.D., Ph.D. was appointed Chief Executive Officer (CEO), effective September 18, 2023.
“Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-09-18–present
-
Current
2021-08-09–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Black Diamond Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Mark A. Velleca CEO
- Mark A. Velleca, M.D., Ph.D. CEO, Chairman
- Mark Velleca CEO
- Erika Jones CFO, Chief Accounting Officer
- Thomas Leggett CFO
- Brent Hatzis-Schoch COO
- Kapil Dhingra Board Member
- Prakash Raman, Ph.D. Board Member
- Robert A. Ingram Board Member
- Shannon Campbell Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.